CD19 and B-cell chronic lymphocytic leukemia: The cells from ibrutinib treated CLL patients showed increased expansion of CD-19 targeted CAR-T Cells (CTL019) and had also reduced the expression of PD-1 on T cells and CD200 on B cells (219).